Interventional Oncology External Innovation

/

/

Interventional Oncology

/

INTO External Innovation team

Meet the Interventional Oncology External Innovation team

We are seeking external innovations to further our intratumoral portfolio.

Stephen Pitt, Ph.D.

Global Head, External Innovation, Interventional Oncology
Ann Ballesteros, Ph.D.

Director, Alliance Management, Interventional Oncology
Chenyu Duke, Ph.D.

Associate Director, Alliance Management, Interventional Oncology
Kai Stoeber, Ph.D.

External Innovation Lead, EMEA, Interventional Oncology
Yao Zhang, Ph.D.

External Innovation Lead, NA, Interventional Oncology

Key areas of interest

At Interventional Oncology, we believe developing new intratumoral and local therapies will help transform the standard of care for cancer patients. Our areas of interest include:

Cytotoxic agents

Drugs with enhanced cytotoxic activity and drug depot technologies/controlled release platforms

Immune activating agents

Pro-inflammatory cytokines and energy-based modalities that activate the immune system.

Therapies that potentiate the effects of radiation

Locally delivered or activated agents, and systemically delivered therapies that enhance local radiation therapy

Platforms

Drug delivery platforms for small molecules, nucleic acid delivery and protein delivery

Procedure enablers

Technologies used to plan, deliver, monitor, and confirm IT therapy delivery, as well as new models for local delivery

Emerging and transformational intratumoral approaches

Emerging technologies

Contact us

We are seeking external innovations to further our intratumoral portfolio. Contact us for partnership opporunities.

Email us